At the Apple New Product Launch on March 10, Apple released the Apple Watch product that everyone was looking forward to. Although Apple removed the Apple Watch's health monitoring function module due to monitoring accuracy issues and certain monitoring items required approval from the US Food and Drug Administration (FDA), Apple also released a new specialization at the press conference. The medical software platform ResearchKit for diseases is expected to turn the iPhone into a medical diagnostic tool through this software.
Regarding the original intention of launching ResearchKit, Apple Chief Operating Officer Jeff Williams said that there are still several limitations in medical research. First, participants are difficult to recruit, and medical research often requires a large number of volunteers to participate. The survey data is subjective; the third is that data is published very frequently. Apple's idea is: Since 700 million iPhones have been sold so far, and each iPhone is a smart hardware that can record user health information, why not use this huge user group to let those who are interested in participate in medicine researching?
ResearchKit is a component package for medical research. It is an open platform that allows medical professionals to create diagnostic apps and access iPhones. At present, the first five Apps have joined the ResearchKit platform, which is jointly launched by the Dana Farber Cancer Institute, the UCLA School of Public Health, the Pennsylvania State University School of Medicine, and the American SageBionetworks Research Center. Share the Journey, MyHeart Counts for Cardiovascular Diseases from Stanford and Oxford, GlucoSuccess for Diabetes by Massachusetts General Hospital, Asthma for Asthma by Mount Sinai Hospital and Cornell University's Will Medical School Health, and mPower for Parkinson's disease (PD) jointly developed by the University of Rochester, China's Capital Medical University Xuanwu Hospital and Sage Bionetworks.
On April 10th, Apple Watch will begin to make an appointment to purchase. On the eve of the 19th World Parkinson's Disease Day (April 11), the newspaper interviewed Professor Chen Wei, deputy director of the Department of Neurology, Xuanwu Hospital, Capital Medical University, who was involved in mPower development, and answered questions about ResearchKit and mPower.
Collect data and break time and space constraints
Professor Chen said that part of the researchKit platform is to collect data for research services. Through the ResearchKit platform, mPower will make it easier for users to sign informed consent to be included in a group clinical study; it can detect Parkinson's disease-related symptoms by sounding the iPhone and tapping the phone screen with a finger, and can also detect by walking and standing the patient. The gait and balance of the patient. At the same time, you can also monitor the response of PD patients to treatment through this app, and so on. These dynamic monitoring data are transmitted to a database for medical research.
The clinical data collected from the consultation consists of two parts, one is the patient's self-reported, the doctor asks the question, and the patient answers. This part can be collected through the mobile platform setting questionnaire. There is also a part that requires a medical background, requires a doctor to explain, and wants to see the patient's reaction on the spot. This part of the data cannot be collected through the mobile platform. From the detection point of view, symptoms such as tremors and slow movements, if the doctor diagnoses the patient in the consultation room, mainly by letting the patient do some movements, the doctor observes the eyes, whether there are symptoms, the condition is heavy or light, and so on. Of course, there are clinically specialized devices for detecting these symptoms, which are more objective. Mobile platforms can replace this part of the objective detection, which is relatively more accurate.
However, Professor Chen also said that Internet medical care is not simply to obtain information and data, but must be based on the establishment of a one-to-one relationship between doctors and patients to solve the patient's personal problems.
Massive data, worth looking forward to
Regarding the amount of data that can be collected through this platform, Professor Chen said that this does not have to worry about it. Within 24 hours of the ResearchKit project announcement, Stanford University received more than 11,000 applications for cardiovascular disease programs, and 5580 people applied for registration for the Parkinson's disease program. Stanford University commented that we need 10,000 cases for a clinical trial and it takes two years to collect through 60 centers around the world. Apple's project has achieved such results in just 24 hours. This is the power of the Internet. Assuming that there are 1 million PD patients among Apple's 700 million users, 10% of them are willing to participate in this project, which is 100,000 patients. The amount of data is very large.
Sweeteners are Food Additives that impart sweetness to soft drinks. Sweeteners can be divided into nutritive sweeteners and non-nutritive sweeteners according to their nutritional value. According to its sweetness, it can be divided into low-sweetness sweet agent and high-sweetness sweet I flavor agent. According to its source can be divided into natural sweeteners and synthetic sweeteners.High safety, good taste, high stability, good water solubility, and reasonable price.Sweeteners,Preservatives,Thickener, Acidity regulator,Food Additives.
We have betaine hydrochloride,Calcium acetate,Dihydromyricetin,Andrographolide,9-methoxypsoralen,Meso-Erythritol,Magnesium lactate,Potassium Sorbate,Dihydromyricetin.
Sweeteners,Preservatives,Thickener, Acidity regulator,Food Additives
Xi'an Henrikang Biotech Co.,Ltd , https://www.xianhenrikangbio.com